Seeking Novel Drug Candidates and Targets for Cardiovascular Disorders

CSL is interested in research developing novel therapeutic candidates or exploring novel drug targets for cardiovascular disease, with a particular focus on rare cardiovascular diseases. CSL has a high interest in engaging with academic research focusing on biologics as well as cell and gene therapies (including gene editing), with a particular interest in plasma-derived protein therapeutics.

Areas of Particular Interest

• Rare Lipid Disorders
• Myocarditis
• Animal Models of Myocarditis
• Familial Cardiomyopathies
• Refractory Angina

Development Stage

• Opportunities at the levels of basic through to late pre‑clinical research 
• Targets validated by patient data, biomarker identification and/or animal models would be advantageous

Submission Information

One‑page research summaries are encouraged, plus any relevant non‑confidential supporting documents

Out of scope

• Opportunities in clinical stages are not of interest
• Small molecule approaches are not within scope, with RNA approaches being of low interest

Opportunity for Collaboration

CSL is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case by case basis. Example outcomes include licensing assets, or research collaborations (such as the creation of a joint steering committee consisting of academics and industry experts in the field at CSL).